Micafungin
- Generic Name
- Micafungin
- Brand Names
- Mycamine
- Drug Type
- Small Molecule
- Chemical Formula
- C56H71N9O23S
- CAS Number
- 235114-32-6
- Unique Ingredient Identifier
- R10H71BSWG
- Background
Micafungin is an antifungal drug. It belongs to the antifungal class of compounds known as echinocandins and exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall.
- Indication
Indicated for the treatment of candidemia, acute disseminated candidiasis, and certain other invasive Candida infections, as well as esophageal candidiasis, and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin is also used as an alternative for the treatment of oropharyngeal candidiases and has been...
- Associated Conditions
- Abscesses, Aspergillosis, Candidemia, Candidiasis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Acute disseminated Candidiasis
- Associated Therapies
- -
Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp
- First Posted Date
- 2016-01-06
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 105
- Registration Number
- NCT02646800
Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia
- First Posted Date
- 2015-05-12
- Last Posted Date
- 2021-11-09
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT02440178
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
- Conditions
- Interventions
- First Posted Date
- 2014-09-19
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- Scynexis, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT02244606
- Locations
- 🇺🇸
University of Texas Health Science Center at Houston, Houston, Texas, United States
🇺🇸University of Miami, Miami, Florida, United States
🇺🇸South Texas Veterans Healthcare System, San Antonio, Texas, United States
Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease
- First Posted Date
- 2014-06-24
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT02172768
- Locations
- 🇳🇱
Radboudumc, Nijmegen, Netherlands
🇧🇪UZ Leuven, Leuven, Belgium
Fluconazole Versus Micafungin in Neonates With Candidiasis
- First Posted Date
- 2014-05-23
- Last Posted Date
- 2014-05-23
- Target Recruit Count
- 100
- Registration Number
- NCT02145832
Use of Micafungin (Mycamine®) as Antifungal Prophylaxis in Haematology and Onco-haematology
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma S.A.S.
- Target Recruit Count
- 150
- Registration Number
- NCT02127788
- Locations
- 🇫🇷
Site, Vandoeuvre-lès-Nancy, France
A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis
- Conditions
- Interventions
- First Posted Date
- 2014-02-07
- Last Posted Date
- 2018-05-23
- Lead Sponsor
- Children's Hospital Medical Center, Cincinnati
- Target Recruit Count
- 9
- Registration Number
- NCT02057289
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
- First Posted Date
- 2013-11-13
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma China, Inc.
- Target Recruit Count
- 59
- Registration Number
- NCT01982071
Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients
- First Posted Date
- 2013-11-01
- Last Posted Date
- 2013-11-01
- Lead Sponsor
- Asan Medical Center
- Target Recruit Count
- 172
- Registration Number
- NCT01974375
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease
- Conditions
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2021-03-12
- Target Recruit Count
- 15
- Registration Number
- NCT01950507
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.